Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus FOAMCOAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus FOAMCOAT.
ALTABAX vs FOAMCOAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic